Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab - Seite 3

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the Securities and Exchange Commission, or SEC, on November 5, 2020, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. 

CONTACT: Media contacts:
Radley Moss
Sema4 Communications
[e-mail]

Investor and Media Inquiries:
Jillian Connell
Merus Investor Relations & Corporate Communications
617-955-4716
[e-mail]